Zacks Research Has Positive Forecast for BDX Q3 Earnings

Becton, Dickinson and Company (NYSE:BDXFree Report) – Analysts at Zacks Research increased their Q3 2026 EPS estimates for shares of Becton, Dickinson and Company in a research report issued on Tuesday, January 21st. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings per share of $4.02 for the quarter, up from their previous forecast of $4.01. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.42 per share.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The firm’s revenue was up 6.9% compared to the same quarter last year. During the same quarter last year, the firm posted $3.42 EPS.

Several other research analysts have also recently issued reports on the stock. Evercore ISI increased their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $283.50.

Read Our Latest Stock Report on BDX

Becton, Dickinson and Company Trading Up 1.0 %

BDX stock opened at $240.21 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $248.42. The firm’s 50-day moving average is $227.44 and its 200 day moving average is $232.83. The company has a market capitalization of $69.66 billion, a PE ratio of 40.44, a P/E/G ratio of 1.74 and a beta of 0.39.

Institutional Trading of Becton, Dickinson and Company

A number of institutional investors have recently bought and sold shares of the stock. Sound Income Strategies LLC boosted its stake in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares in the last quarter. Central Pacific Bank Trust Division boosted its stake in Becton, Dickinson and Company by 22.5% in the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 45 shares in the last quarter. Tompkins Financial Corp raised its position in Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares during the last quarter. Birch Capital Management LLC lifted its stake in Becton, Dickinson and Company by 0.4% during the 3rd quarter. Birch Capital Management LLC now owns 11,773 shares of the medical instruments supplier’s stock valued at $2,838,000 after acquiring an additional 48 shares during the period. Finally, Radnor Capital Management LLC lifted its stake in Becton, Dickinson and Company by 1.7% during the 3rd quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock valued at $708,000 after acquiring an additional 48 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $221.01, for a total value of $990,787.83. Following the completion of the sale, the executive vice president now directly owns 24,345 shares in the company, valued at $5,380,488.45. This trade represents a 15.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Shana Carol Neal sold 788 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the sale, the executive vice president now owns 16,201 shares of the company’s stock, valued at $3,807,235. This trade represents a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 9,844 shares of company stock worth $2,210,716. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th were issued a $1.04 dividend. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.73%. The ex-dividend date was Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 70.03%.

About Becton, Dickinson and Company

(Get Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Stories

Earnings History and Estimates for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.